Yhdysvallat - englanti - NLM (National Library of Medicine)

atlantic biologicals corps - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate 1 g in 1 g - sodium polystyrene sulfonate, usp is indicated for the treatment of hyperkalemia. sodium polystyrene sulfonate, usp is contraindicated in the following conditions: patients with hypokalemia, patients with a history of hypersensitivity to polystyrene sulfonate resins, obstructive bowel disease, neonates with reduced gut motility (postoperatively or drug induced) and oral administration in neonates (see ). precautions

Yhdysvallat - englanti - NLM (National Library of Medicine)

sunrise pharmaceutical, inc. - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium cation 4.1 meq in 1 g - sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. limitation of use : sodium polystyrene sulfonate for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2) ] sodium polystyrene sulfonate is contraindicated in patients with the following conditions: - hypersensitivity to polystyrene sulfonate resins - obstructive bowel disease - neonates with reduced gut motility risk summary sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients, as in adults, sodium polystyrene sulfonate is expected to bind potassium at the pract

Yhdysvallat - englanti - NLM (National Library of Medicine)

eci pharmaceuticals, llc - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium cation 4.1 meq in 1 g - sodium polystyrene sulfonate is indicated for the treatment of hyperkalemia. limitation of use: sodium polystyrene sulfonate should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2)] . sodium polystyrene sulfonate is contraindicated in patients with the following conditions: - hypersensitivity to polystyrene sulfonate resins - obstructive bowel disease - neonates with reduced gut motility risk summary sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients, as in adults, sodium polystyrene sulfonate is expected to bind potassium at the practical exchange ratio of 1meq po

Yhdysvallat - englanti - NLM (National Library of Medicine)

marlex pharmaceuticals inc - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium cation 4.1 meq in 1 g - sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. sodium polystyrene sulfonate is contraindicated in the following conditions: patients with hypokalemia, patients with a history of hypersensitivity to polystyrene sulfonate resins, obstructive bowel disease, neonates with reduced gut motility (postoperatively or drug induced) and oral administration in neonates. (see precautions )

Belgia - englanti - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sanofi belgium sa-nv - calcium polystyrene sulfonate 14,99 g - powder for oral/rectal suspension - 14,99 g - polystyrene sulfonate calcium 999.9 mg/g - polystyrene sulfonate

Australia - englanti - Department of Health (Therapeutic Goods Administration)

catalent australia pty ltd - polystyrene sulfonate - calcium -

Kanada - englanti - Health Canada

sanofi-aventis canada inc - calcium polystyrene sulfonate - powder for solution - 999mg - calcium polystyrene sulfonate 999mg - potassium-removing agents

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - calcium polystyrene sulfonate - powder for oral or rectal suspension - 999mg/1gram

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - calcium polystyrene sulfonate - powder for oral or rectal suspension - 999mg/1gram

Australia - englanti - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium polystyrene sulfonate, quantity: 999.3 mg/g - powder - excipient ingredients: saccharin; vanillin - treatment of hyperkalaemia.